Insulet opened higher at $154.60, compared with its previous close of $152.50. In the last trading session, the stock traded between $150.31 and $154.95. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Insulet is now worth
$ 48.56
resulting in a loss of
$ 51.44 (51.44%)
Note: Past profits do not guarantee future returns.
Rating from 20 Analysts
Today's Change
$-1.95 (-1.28%)
Day High
$154.95
Day Low
$150.31
Day Open
$154.60
Prev Close
$152.50
Volume
3,08,882
1W Return
1.66%
1M Return
13.31%
3M Return
-11.66%
6M Return
-5.91%
1Y Return
-52.38%
Market Cap ($ Mn)
10,442
PE Ratio
27.18
PB Ratio
7.08
PEG Ratio
0.27
ROE
17.90%
ROCE
14.11%
EPS (TTM)
$1.37
1 Week
1.66%
1 Month
13.31%
3 Months
-11.66%
6 Months
-5.91%
9 Months
-40.98%
Insulet Q2FY26 Results: Revenue up 23% YoY, adjusted EPS rises 41.5%
Total revenue reached $802 million, up 23.5% YoY on a reported basis. Adjusted EPS rose 41.5% to $1.66, outpacing revenue growth. Adjusted operating margin expanded by 140 bps to 19.3%. Full-year revenue growth guidance revised to 20-22% due to type 2 retention trends.
22 days agoInsulet to present at Bernstein Healthcare Leaders and Disruptors forum
Insulet management to present at Bernstein Healthcare Forum on September 24, 2026. Presentation scheduled for 12:30 pm Eastern Time. Live webcast and replay available on Insulet Investor Relations website. Company highlights Omnipod 5 automated insulin delivery system capabilities.
1mo agoInsulet investors urged to act before Aug 31 lead plaintiff deadline
Deadline to seek appointment as lead plaintiff in Insulet securities class action is August 31, 2026. Lawsuit alleges concealed manufacturing defects in Omnipod systems affecting 8.5% of 2025 production. Shares fell from $236 to $146 following two Medical Device Corrections in March and May 2026. Multiple law firms urge investors to contact them regarding potential claims and lead plaintiff status.
1mo agoInsulet to present at Wells Fargo healthcare conference in Boston
Insulet management presents at Wells Fargo conference on September 9, 2026. Session scheduled for 2:15 pm ET in Boston. Live webcast and replay available via investor relations site. Company highlights Omnipod 5 automated insulin delivery system.
2mo agoBTIG Downgrades Insulet Corp to Neutral From Buy Rating
BTIG analyst Marie Thibault downgraded Insulet Corp (NASDAQ: PODD) from Buy to Neutral. The filing does not disclose specific drivers or price targets for the change. Investors should monitor for further commentary from the firm.
2mo agoInsulet partners with Calm to launch diabetes mindfulness tools
Insulet Corporation has partnered with Calm to launch The Mind in Range Collection, offering free mindfulness resources like a sleep story by Lila Moss to support the mental well-being of the diabetes community. The initiative addresses high rates of anxiety and poor sleep among patients, with Insulet's research showing significant demand for holistic care. The partnership aims to normalize mental health conversations in diabetes management and reduce the emotional burden of the disease.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $104.57 | +1.88% | $1,80,946.15M | 36.28 | |
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 |
An investment of $100 made 5 years ago in Insulet is now worth
$ 48.56
resulting in a loss of
$ 51.44 (51.44%)
Note: Past profits do not guarantee future returns.
